The new HORWIN SK3 PLUS e-scooter - one step ahead
10.5.2024 09:01:13 CEST | news aktuell GmbH | Press release
The electric two-wheeler manufacturer HORWIN is expanding its scooter range with a high-performance model. The popular SK series has been taken one step further - which is what the term "PLUS" stands for in the new SK3 model.

The sporty e-scooter now has a more powerful mid-motor. With a peak output of 8.64 kW, the vehicle can reach speeds of up to 100 km/h, outperforming the traditional SK3. The new, modern belt drive minimises noise and extends the service life of the drive. With two 45 Ah batteries, the scooter in the L3e class has a range of around 130 kilometres. A full charge takes around 4.5 hours.
The sleek e-scooter delivers automotive quality with its high-quality paintwork and powerful full LED headlights. Not only are the ergonomically optimised dimensions extra large for perfect seating comfort. The clear LCD display with a screen diagonal of 7 inches also leaves no important information unanswered for the rider.
The SK3 PLUS is equipped with numerous other technical refinements. These include a battery, FOC energy and CBS brake management system, an electronic anti-theft device, keyless go and an OBD interface.
The new model is now available from specialist dealers. More information at www.horwinglobal.com or www.horwin.eu
HORWIN Inc. is based in Changzhou / China and has a well-developed dealer network in Europe. The vehicles are produced at HORWIN Global in China specifically for European requirements in the areas of quality, safety and dimensioning. The European central warehouse is located in Austria, ensuring a rapid supply of spare parts in Europe.
Query information:
HORWIN International Market | Sales Office: horwin@horwinglobal.com
HORWIN European Market | Sales Office: info@horwin.eu
Images


Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom